Lipid Nanoparticle: Unlocking the Future of Medicine
LNPs are known to be a versatile delivery platform owing to their ability to encapsulate and deliver broad range of molecules, including nucleic acids, proteins / peptides and small molecules. These delivery systems have the ability to protect the encapsulated fragile therapeutic from degradation, enable enhanced solubility / bioavailability and facilitate controlled release in targeted regions of the body. It is worth mentioning that LNPs have gained significant traction during the COVID-19 pandemic, owing to their role in the development of mRNA vaccines, namely COMIRNATY (developed by Pfizer-BioNTech) and Spikevax (developed by Moderna).
However, lipid nanoparticle manufacturing is a cost-intensive and complex process that requires specialized facilities, advanced equipment and operational expertise. The aforementioned constraints, coupled to the growing demand for nanoparticle-based therapeutics, have prompted players to increasingly rely on lipid nanoparticle CMO and LNP technology developers, to leverage their resources and optimize the overall production cost.
Visit: https://www.rootsanalysis.com/reports/lipid-nanoparticle-manufacturing-market.html
Lipid Nanoparticle Manufacturing Market
According to Roots Analysis, the lipid nanoparticle manufacturing market is estimated to be USD 0.66 billion in 2023 and is anticipated to grow at a CAGR of 11.8% till 2035. Presently, solid lipid nanoparticles (SLNs) are anticipated to capture majority share in the lipid nanoparticle manufacturing market. Amongst the key geographical regions, more than 45% of the global market of lipid nanoparticle manufacturing is anticipated to be captured by players based in North America, in 2035.
Growth of lipid nanoparticle manufacturing market is driven by several factors, such as rising prevalence of chronic diseases, growing demand for nanoparticle-based drugs and ongoing technological advancements in this domain.
Lipid Nanoparticles Manufacturing Market Landscape
The current market landscape features the presence of around 45 lipid nanoparticle contract manufacturers, spread across the globe. The service providers landscape is fragmented, featuring a mix of several very large, large, mid-sized and small companies. Majority of the players engaged in this domain are headquartered in North America; of these, over 90% are based in the US. It is worth mentioning that majority (60%) of the facilities manufacture LNPs for encapsulating and delivering different types of nucleic acids, such as messenger RNA (mRNA), small interfering RNA (siRNA) and deoxyribonucleic acid (DNA).
Further, over 30 companies are engaged in the development of lipid nanoparticle technology; around 60% of these players were established post-2010. Notably, most (93%) of the LNP technology support the delivery of formulations through injectable route, followed by nasal route (30%).
The Increasing Interest in Lipid Nanoparticle Manufacturing Field is also Reflected in Recent Partnership Activity
In recent years, several partnerships have been established by industry stakeholders, in order to consolidate their presence in this field, and enhance their capabilities and product portfolio to meet the growing demand for LNP-based drugs. Most of the partnerships are focused on research and development, product / technology licensing, and development of lipid nanoparticle-based drugs.
Leading Companies in Lipid Nanoparticle Contract Manufacturing and Technologies Domain
Examples of key lipid nanoparticle contract manufacturing companies (which have also been captured in this report) include BIOVECTRA, Curapath, Curia, Emergent BioSolutions, EUROAPI, Evonik and Precision NanoSystems. In addition, companies engaged in developing LNP technology include (which have been profiled in the market report) Acuitas Therapeutics, Ascendia Pharmaceuticals, Integrated Nanotherapeutics, leon-nanodrugs, Matinas BioPharma, Pantherna Therapeutics and TLC Biosciences.
